vs
BENCHMARK ELECTRONICS INC（BHE）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是BENCHMARK ELECTRONICS INC的1.1倍（$772.1M vs $677.3M），Revvity净利率更高（12.7% vs 1.9%，领先10.8%），BENCHMARK ELECTRONICS INC同比增速更快（11.4% vs 5.9%），Revvity自由现金流更多（$161.8M vs $48.1M），过去两年Revvity的营收复合增速更高（9.0% vs -0.7%）
Benchmark Electronics Inc是总部位于美国亚利桑那州坦佩市的电子制造服务（EMS）、原始设计制造（ODM）及原始设备制造（OEM）企业，为客户提供专业的合同制造服务，业务覆盖全球多个区域的电子产业链需求。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BHE vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$677.3M
营收增速更快
BHE
高出5.5%
5.9%
净利率更高
RVTY
高出10.8%
1.9%
自由现金流更多
RVTY
多$113.7M
$48.1M
两年增速更快
RVTY
近两年复合增速
-0.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $677.3M | $772.1M |
| 净利润 | $13.0M | $98.4M |
| 毛利率 | 10.2% | — |
| 营业利润率 | 3.2% | 14.5% |
| 净利率 | 1.9% | 12.7% |
| 营收同比 | 11.4% | 5.9% |
| 净利润同比 | 257.4% | 3.9% |
| 每股收益（稀释后） | $0.17 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHERVTY
| Q1 26 | $677.3M | — | ||
| Q4 25 | $725.8M | $772.1M | ||
| Q3 25 | $702.6M | $698.9M | ||
| Q2 25 | $665.7M | $720.3M | ||
| Q1 25 | $654.6M | $664.8M | ||
| Q4 24 | $683.6M | $729.4M | ||
| Q3 24 | $680.0M | $684.0M | ||
| Q2 24 | $686.7M | $691.7M |
净利润BHERVTY
| Q1 26 | $13.0M | — | ||
| Q4 25 | — | $98.4M | ||
| Q3 25 | $14.3M | $46.7M | ||
| Q2 25 | $972.0K | $53.9M | ||
| Q1 25 | $3.6M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $15.4M | $94.4M | ||
| Q2 24 | $15.5M | $55.4M |
毛利率BHERVTY
| Q1 26 | 10.2% | — | ||
| Q4 25 | 10.2% | — | ||
| Q3 25 | 9.7% | 53.6% | ||
| Q2 25 | 9.7% | 54.5% | ||
| Q1 25 | 9.7% | 56.5% | ||
| Q4 24 | 9.9% | — | ||
| Q3 24 | 9.8% | 56.3% | ||
| Q2 24 | 9.9% | 55.7% |
营业利润率BHERVTY
| Q1 26 | 3.2% | — | ||
| Q4 25 | 2.8% | 14.5% | ||
| Q3 25 | 3.4% | 11.7% | ||
| Q2 25 | 3.1% | 12.6% | ||
| Q1 25 | 1.8% | 10.9% | ||
| Q4 24 | 4.2% | 16.3% | ||
| Q3 24 | 4.1% | 14.3% | ||
| Q2 24 | 4.0% | 12.4% |
净利率BHERVTY
| Q1 26 | 1.9% | — | ||
| Q4 25 | — | 12.7% | ||
| Q3 25 | 2.0% | 6.7% | ||
| Q2 25 | 0.1% | 7.5% | ||
| Q1 25 | 0.6% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 2.3% | 13.8% | ||
| Q2 24 | 2.3% | 8.0% |
每股收益（稀释后）BHERVTY
| Q1 26 | $0.17 | — | ||
| Q4 25 | $0.16 | $0.86 | ||
| Q3 25 | $0.39 | $0.40 | ||
| Q2 25 | $0.03 | $0.46 | ||
| Q1 25 | $0.10 | $0.35 | ||
| Q4 24 | $0.43 | $0.77 | ||
| Q3 24 | $0.42 | $0.77 | ||
| Q2 24 | $0.43 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $324.9M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | $2.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BHERVTY
| Q1 26 | $324.9M | — | ||
| Q4 25 | $322.1M | $919.9M | ||
| Q3 25 | $285.4M | $931.4M | ||
| Q2 25 | $264.6M | $991.8M | ||
| Q1 25 | $355.3M | $1.1B | ||
| Q4 24 | $315.2M | $1.2B | ||
| Q3 24 | $324.4M | $1.2B | ||
| Q2 24 | $309.3M | $2.0B |
总债务BHERVTY
| Q1 26 | — | — | ||
| Q4 25 | $206.8M | — | ||
| Q3 25 | $212.6M | — | ||
| Q2 25 | $203.4M | — | ||
| Q1 25 | $268.9M | — | ||
| Q4 24 | $250.5M | — | ||
| Q3 24 | $272.0M | — | ||
| Q2 24 | $283.6M | — |
股东权益BHERVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $7.3B | ||
| Q3 25 | $1.1B | $7.4B | ||
| Q2 25 | $1.1B | $7.6B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B |
总资产BHERVTY
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $12.2B | ||
| Q3 25 | $2.1B | $12.1B | ||
| Q2 25 | $2.0B | $12.4B | ||
| Q1 25 | $2.1B | $12.4B | ||
| Q4 24 | $2.1B | $12.4B | ||
| Q3 24 | $2.1B | $12.8B | ||
| Q2 24 | $2.2B | $13.4B |
负债/权益比BHERVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.23× | — | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | 0.26× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $47.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $48.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 7.1% | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 3.61× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $108.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BHERVTY
| Q1 26 | $47.0M | — | ||
| Q4 25 | $58.7M | $182.0M | ||
| Q3 25 | $36.6M | $138.5M | ||
| Q2 25 | $-2.8M | $134.3M | ||
| Q1 25 | $31.5M | $128.2M | ||
| Q4 24 | $45.9M | $174.2M | ||
| Q3 24 | $39.0M | $147.9M | ||
| Q2 24 | $55.8M | $158.6M |
自由现金流BHERVTY
| Q1 26 | $48.1M | — | ||
| Q4 25 | $48.2M | $161.8M | ||
| Q3 25 | $25.8M | $120.0M | ||
| Q2 25 | $-13.8M | $115.5M | ||
| Q1 25 | $28.1M | $112.2M | ||
| Q4 24 | $37.2M | $149.8M | ||
| Q3 24 | $29.2M | $125.6M | ||
| Q2 24 | $48.2M | $136.6M |
自由现金流率BHERVTY
| Q1 26 | 7.1% | — | ||
| Q4 25 | 6.6% | 21.0% | ||
| Q3 25 | 3.7% | 17.2% | ||
| Q2 25 | -2.1% | 16.0% | ||
| Q1 25 | 4.3% | 16.9% | ||
| Q4 24 | 5.4% | 20.5% | ||
| Q3 24 | 4.3% | 18.4% | ||
| Q2 24 | 7.0% | 19.7% |
资本支出强度BHERVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 1.5% | 2.6% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 1.3% | 3.4% | ||
| Q3 24 | 1.4% | 3.3% | ||
| Q2 24 | 1.1% | 3.2% |
现金转化率BHERVTY
| Q1 26 | 3.61× | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | 2.57× | 2.97× | ||
| Q2 25 | -2.90× | 2.49× | ||
| Q1 25 | 8.65× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 2.54× | 1.57× | ||
| Q2 24 | 3.59× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHE
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
